Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu kazuistiky, časopisecké články
PubMed
31288153
DOI
10.1016/j.intimp.2019.105728
PII: S1567-5769(19)30870-7
Knihovny.cz E-zdroje
- Klíčová slova
- Acute kidney injury, Chemotherapy rechallenge, Immune haemolytic anemia, Oxaliplatin, Type II hypersensitivity reaction,
- MeSH
- adenokarcinom komplikace diagnóza farmakoterapie MeSH
- akutní poškození ledvin MeSH
- antitumorózní látky škodlivé účinky terapeutické užití MeSH
- desenzibilizace imunologická MeSH
- hemolýza MeSH
- hormony kůry nadledvin terapeutické užití MeSH
- léková alergie diagnóza farmakoterapie etiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- metastázy nádorů MeSH
- nádory rekta komplikace diagnóza farmakoterapie MeSH
- nežádoucí účinky léčiv diagnóza farmakoterapie etiologie MeSH
- oxaliplatin škodlivé účinky terapeutické užití MeSH
- senioři MeSH
- trombocytopenie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- Názvy látek
- antitumorózní látky MeSH
- hormony kůry nadledvin MeSH
- oxaliplatin MeSH
BACKGROUND: Rechallenge with oxaliplatin is common in the treatment of colorectal cancer and increases the risk of a detrimental oxaliplatin-induced immune reaction. Allergic reactions to oxaliplatin may be partially avoided by desensitization protocols involving immune suppressive drugs, slow administration and gradually increasing chemotherapeutic doses. However, non-IgE-mediated immunopathologic reactions to oxaliplatin remain challenging and may be potentially life-threatening. CASE PRESENTATION: Here we report two potentially fatal cases of type II hypersensitivity to oxaliplatin in metastatic colorectal cancer patients. Both patients manifested with severe thrombocytopenia, intravascular haemolysis, and acute kidney injury 4-6 h after oxaliplatin administration in a rechallenge setting. Serology revealed that the reactive entity for immune haemolysis was an IgG oxaliplatin-induced antibody. The course of anti-cancer treatment and severe adverse event after oxaliplatin rechallenge including diagnostic dilemma and the results of detailed routine clinical chemistry and hematology testing are described. Extended immunohaematology/serology testing revealed that the oxaliplatin-induced IgG antibody was present in the circulation prior to the onset of hypersensitivity, persisted for months and elicited cross-reactivity with other platinum agents. CONCLUSION: Development of type II hypersensitivity reaction manifesting as a sudden onset of severe thrombocytopenia and immune haemolysis must be considered in patients treated with oxaliplatin, especially those on long-term therapy or when rechallenged. Step-wise diagnosis involves clinical presentation, detection of haemolysis in patient's blood and/or urine, evaluation of platelet count, and direct anti-globulin Coombs test.
Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic
Department of Laboratory Medicine Masaryk Memorial Cancer Institute Brno Czech Republic
Citace poskytuje Crossref.org
